Introduction
Inhibitors of triphosphate nucleotide synthesis, such as PALA (N-phosphonoacetyl-L-aspartate), methotrexate or coformycin, have been extensively used to study the ability of tumor cells to amplify the drug's target enzyme-encoding gene (for reviews, see Sharma and Schimke, 1994; Stark, 1986) . Under limiting amounts of dNTPs, most cells stop cycling or die whereas in rare cells, DNA rearrangements lead to ampli®cation of a gene that can mediate resistance to the selective drug. The p53 protein is part of a pathway that allows cells to arrest cell cycle progression in response to the presence of antimetabolites Chen et al., 1996; Di Leonardo et al., 1993; Linke et al., 1996; Livingstone et al., 1992; Yin et al., 1992) . In Li-Fraumeni syndrome ®broblasts, heterozygous for TP53 mutation, it was shown that the presence of a wild-type p53 protein correlates with a non-permissive status for ampli®cation of the CAD (carbamoylphosphate synthetase/aspartate transcarbamoylase/dihydroorotase) gene under PALA selection (Livingstone et al., 1992; Yin et al., 1992) . The permissivity of p53-de®cient cells to ampli®cation may derive from the persistence of broken DNA due to the dysfunctioning of the cell cycle checkpoint. Broken DNA was described as the ®rst step of the ampli®cation process (Stark, 1993; Toledo et al., 1993) . Replication of broken chromosomes leads to the formation of dicentric chromosomes (Di Leonardo et al., 1993; Smith et al., 1990; Toledo et al., 1992; Trask and Hamlin, 1989) , and subsequent breakage-fusion-bridge cycles, originally described by McClintock (McClintock, 1939 ) generate duplications, deletions and ladderlike structures bearing ampli®ed genes which were ®rst observed in rodent cells (Ma et al., 1993; Toledo et al., 1992; Windle et al., 1991) .
In the present study, we examined the eect of TP53 status on the permissivity of cancer cells to amplification under PALA selective pressure. Colon LoVo cells were chosen because they have wild-type TP53 and a rather simple near-diploid karyotype. We showed that PALA-resistant colonies were generated from both parental and 143Ala-mutated TP53 transfected LoVo cells and increase in CAD gene copy number mediated PALA resistance in all the clones. Gene ampli®cation sensu stricto was rarely observed. However, the types of chromosomal aberrations dier. LoVo cells acquired PALA resistance mostly through the acquisition of very few extra CAD gene copies resulting from either chromosome rearrangements, in mutated TP53 cells or gains, in wild-type TP53 cells. This prompted us to compare these results to the two main cytogenetic patterns described in colorectal carcinogenesis (Muleris et al., 1990) . The eect of TP53 mutational status on the chromosomal pattern involved in gene amplification leading to PALA resistance is discussed.
Results

Cytogenetic characterization and TP53 status of LoVo cells
The karyotype of the LoVo cell line (Figure 1 ) is characterized by a trisomy of chromosomes 5, 7 and 15 leading to a modal number of 49 chromosomes and three reciprocal translocations: t(2;12)(q22;p12.1), t(7;18)(q31.3;q22) and t(11;14)(p14;q21). It remains stable during in vitro passages. The translocation aecting one of the two chromosomes 2, on which the CAD gene maps on 2p21-p22, enabled both homologs to be distinguished. The expected wild-type TP53 status of the LoVo cell line (Cottu et al., 1996) was con®rmed by denaturing gradient gel electrophoresis analysis (data not shown) and immunocytochemical staining (Figure 2a ).
Cytogenetic characterization, vector integration and p53 expression in TP53-transfected LoVo clones
The karyotypes of the clones transfected with the mutant plasmid were similar to that of the parental LoVo cells except that extra copies of chromosomes 5 and/or 15 were not always observed (Table 1) . Vector integration was veri®ed using Southern blotting (data not shown) and FISH with the SN3 probe (data not shown). The signal corresponding to the exogenous TP53 was detected at positions that diered from one clone to another, but was constant within each clone: on 4q32-q33, der(2)p13, 4q33-q34 and 10q21, in 143X3, 143X14, 143X19 and 143X20, respectively. Although very close, the vector integration sites in the 143X3 and the 143X19 transfected cells were distinct, and this dierence was con®rmed by Southern blotting analysis that exhibited dierent digestion patterns. In all transfected clones, signals corresponding to the endogenous TP53 genes, also detected by the probe, were localized at their expected position on chromosome 17p arm. The LoVo T1 and T2 clones issued from the transfection with the vector alone were considered as controls. Western blot analyses showed a comparable amount of p53 protein in parental and control LoVo cells, a slight increase in the 143X3 and 143X14 transfected clones and a higher increase in the 143X19 and 143X20 transfected clones (Figure 3b ). The excess of protein detected in mutated-TP53 transfected clones could be assigned to the expression of the mutated p53 protein by referring to ELISA analyses ( Figure 3a ). As expected, no mutated protein was detected in both control LoVo clones (Table 2) . Immunocytochemistry showed a slight p53 staining in 143X3 and 143X14 cells and a stronger one in 143X19 and 143X20 cells (Figure 2b ).
PALA-resistance of parental and TP53-transfected LoVo cells
The ability of parental LoVo cells to form resistant colonies when exposed to 100 mM PALA diered from one experiment to another, varying from no detectable colonies to 5.5610
75
. In control transfected clones LoVo T1 and T2, a comparable frequency of PALAresistant colonies was observed.
The frequency of PALA-resistant colonies diered according to the transfected clones ( Table 2 ). The clone 143X3 weakly expressed mutant p53 and yielded very few resistant colonies while many quiescent cells remained stuck to the bottom of the Petri dishes. When these quiescent cells were replated in 100 mM PALA-containing medium, almost all died; only one colony could be obtained and further analysed. 143X14 cells died after a few days of selection in 100 mM PALA, and no cells remained on the bottom of the Petri dishes. In contrast, 143X19 and 143X20 clones, which strongly expressed mutant p53, consistently yielded PALA-resistant colonies at a frequency of 7.2610 75 and 7.9610
, respectively.
Cytogenetic characterization of the drug-resistance mechanisms
Resistant colonies issued from parental and transfected LoVo cells were karyotyped and examined by FISH to evaluate CAD ampli®cation. The CAD copy number was increased in all colonies but dierent resistance mechanisms were observed (Table 1) . Among the 12 resistant colonies originating from parental LoVo cells, ten showed a gain of one normal chromosome 2 bearing the CAD gene ( Figure 4) ; one of them, L9, gained both the normal and the derivative chromosome 2, giving it a total of four CAD copies. Colonies L11 and L12 exhibited rearrangements of chromosome 2 increasing their CAD copy numbers to three or four, respectively.
In seven of the nine resistant colonies derived from the 143X19 clone, the CAD gene copy number was increased through rearrangements aecting one chromosome 2 (Figure 5a ± d): colony A1 showed a tandem ampli®cation forming a small homogeneously staining region (hsr), while in the others, the gain of CAD copies resulted from rearrangements of chromosome 2, leading to either the formation of an extra isochromosome i(2)(p10) (A2 and A3) or the translocation of an extra 2p arm segment containing the CAD gene onto the long arm of chromosome 2 (A4, A5 and A6) and/ or onto another chromosome (A6 and A7). Colony A6 was tetraploid. The PALA-resistance in colonies A8 and A9 was associated with an extra copy of a normal chromosome 2.
In the three resistant colonies issued from the 143X20 clone, the CAD gene copy number was increased through either a gain of an isochromosome 2p (B1) or a complex rearrangement leading to the formation of an hsr containing the CAD gene (B2) (Figure 5e ), or a gain of a normal chromosome 2 (B3). 47,idem,der(2)t(2;2)(q35;p16),der(7)t(2;7)(q35;q31) [7] /46,idem, der(2)t(2;2)(q35;p16),der(7)t(2;7)(q35;q31),add (13) 48,XY,t(2;12)(q22;p12.1),+5,+7,t(7;18)(q31.3;q22),t(11;14)(p14;q21) [9] 48,idem,der(2)t(2;2)(q35-36;p11-12)[3]/49,idem,der(2)t(2;2)(q35-36;p11-12) x2[2]/49,idem,der(2)t(2;2)(q35-36;p11-12),+i(2)(p10) Chromosomal pathway and TP53 status P Soulie et al
The unique PALA-resistant 143X3 colony showed a gain of the CAD gene copy number through the formation of an intrachromosome 2 rearrangement associated with an isochromosome 2p in a subclone.
The mechanisms of resistance observed in parental LoVo cells (gain of one chromosome 2 in 10/12 colonies) and in transfected clones expressing mutant p53 (chromosome rearrangements in 10/13 colonies) statistically dier (w 2 =9.1, d=1, P50.002).
Rate of unstable rearrangements
The rate of unstable rearrangements per metaphase was 0.44 and 0.47 in parental and PALA resistant LoVo cells, respectively. In transfected clones yielding PALA-resistant colonies (143X3, 143X19 and 143X20), it was of 0.37 before PALA selection and 0.36 in resistant colonies.
Discussion
Relationship between mutated p53 expression and PALA resistance
In transfected cells, a relationship between the amount of mutant p53 and the ability to form resistant colonies was observed. The two transfected clones that strongly expressed mutant p53 protein (143X19 and 143X20) repeatedly formed PALA-resistant colonies at a high frequency. By contrast, transfected clones 143X3 and 143X14, which weakly expressed mutant p53, yielded very few or no colonies. These data are in agreement with previous experiments in which wild-type TP53 gene was introduced into post-crisis Li-Fraumeni ®broblasts lacking functional p53. Only the transformants that weakly expressed wild-type p53 generated PALA-resistant colonies, while those strongly expressing wild-type p53 did not (Yin et al., 1992) .
Mechanisms of CAD ampli®cation in parental and transfected LoVo cells
The increase in CAD gene copy number mediated PALA resistance in all the clones analysed, independently of their TP53 status. However, this increase was achieved in dierent ways: gains of entire chromosomes 2, gains of isochromosomes 2p, formation of derivative chromosomes carrying at least one additional CAD copy or formation of hsr. Such distinct patterns of CAD ampli®cation were described in human cell lines (Smith et al., 1995 (Smith et al., , 1997 and in SV40-or HPV16-infected human ®broblasts (Schaefer et al., 1993; White et al., 1994) , in contrast to rodent cells in which the . Native loci of CAD onto the normal chromosome 2 and the derivative chromosome der(2)t(2;12)(q22;p12.1) are indicated by arrow heads. Extra copies of CAD are indicated by arrows gene ampli®cation by ladder-like structures is mainly observed. In our study, striking dierences in the cytogenetic patterns of CAD ampli®cation were noted as a function of the TP53 status of the cells. In parental LoVo cells expressing wild-type p53, PALAresistance was associated with a gain of one normal chromosome 2 in 10/12 colonies and with a chromosomal rearrangement in the remaining 2/12 colonies. In transfected clones expressing mutant p53, the ratios were reversed: the resistance occurred through chromosomal rearrangements in 10/13 cases, while a normal chromosome 2 was gained in 3/13 colonies, only. Data of the literature support our results. PALA resistance of normal human ®broblasts infected with E6 and E7 viral oncogenes showed that in cells expressing E6, which binds to and degrades the p53 protein, the drug-resistant clones exhibited CAD gene ampli®cation in addition to multiple rearrangements, whereas in cells expressing E7, which is responsible for a p53-independent alteration in cellcycle control, drug resistance was achieved through chromosome 2 polysomy (White et al., 1994) . In the p53 wild-type LIM1215 cells, whose karyotype is neardiploid with few rearrangements, PALA resistance was related to a gain of chromosome 2. At contrast, in the p53 null Saos cell line, the karyotype is highly hyperploid and rearranged and the increase of CAD copies is related to structural rearrangements (Smith et al., 1997) .
Several hypotheses can be proposed to explain the dierent cytogenetic patterns of CAD gene increase in parental and transfected LoVo cells. That of preexisting variants exhibiting either an extra chromosome 2 or ampli®cation of CAD is unlikely, because the protocol used cell populations small enough to be statistically devoid of pre-existing variants . The high occurrence of chromosome 2 rearrangements in the transfected clones may also re¯ect an increased frequency of unstable rearrangements due to the strong expression of mutant p53 in these cells. Indeed, increased chromosome breakage associated with enhanced mutant p53 expression has been reported in the human nonpolyposis colorectal cancer LIM1215 cell line (Agapova et al., 1996) . However, in our study, the rate of unstable rearrangements, which re¯ects that of chromosome alterations at each cell generation, was found to be similar in wildtype and mutant p53-expressing LoVo cells. Moreover, the rate of unstable rearrangements in the selected PALA resistant clones is similar to that observed before selection, showing that PALA did not select cells that were more sensitive to mutagenesis. Thus, 143Ala-mutated TP53 gene permits the maintenance of chromosome alterations rather than leads to their induction in LoVo cells. A possible explanation is that the dysfunctioning of cell cycle control checkpoint in TP53 mutated cells may allow the persistance of cells with chromosomal rearrangements that otherwise would have been counterselected or would have underwent apoptosis.
Comparison with the cytogenetic patterns of colorectal tumors
A parallel can be drawn between the induced alterations of the LoVo cells karyotype under PALA selective pressure and those naturally occurring in colorectal carcinogenesis, where two main pathways were described (Muleris et al., 1990; Remvikos et al., 1997) . One pathway, the TT (Trisomic Type), is characterized by progressive gains of normal chromosomes, a low rate of clonal structural rearrangements, mostly of the balanced type, frequent DNA-repeat instability and only few TP53 mutations. Thus, the parental LoVo cells, carrying three trisomies, three balanced rearrangements, DNA repeat instability (Umar et al., 1994) and no TP53 mutation is typical of the TT. Under standard growth conditions, the karyotype of this cell line remained unchanged, suggesting that it acquired functional stability and further chromosome gains would not procure any better advantage. When exposed to PALA, the gain of one chromosome 2 is selected presumably because it provides an extra copy of the CAD gene. Gains of chromosomes 5, 12 and 15 are also occasionally associated. Thus, the evolution of LoVo cells under PALA selection follows a typical TT pathway. The other pathway, the MT (Monosomic Type), is characterized by a high rate of unbalanced clonal rearrangements associated with recurrent chromosome losses and frequent TP53 mutations. Transfected LoVo cells, both before and after PALA selection, exhibited a strong tendency to lose chromosomes, in particular one copy of chromosomes 5 and 15, which were originally in triplicate. After PALA selection, they principally acquired unbalanced rearrangements (of chromosome 2 and others), like MT colorectal cancers. Thus, the presence of the 143Ala-mutated TP53 would confer to the transfectants the ability to amplify DNA, possibly through the dysfunctioning of the cell cycle checkpoint, which would overcome the trisomic behavior.
TP53, gene ampli®cation and cell cycle control
Fusions of normal and tumor cells were performed initially to demonstrate that permissivity to gene ampli®cation was a recessive genetic trait . In Li-Fraumeni ®broblasts, heterozygous for the TP53 mutation, the presence of one wild-type TP53 allele prevents gene ampli®cation (Livingstone et al., 1992; Yin et al., 1992) . In our model, the loss of the wild-type alleles, shown to be functional in the LoVo cell line (Pocard et al., 1996) , was not required for permissivity to ampli®cation. This dierence has several possible interpretations, such as dierences in the genetic background of the cells or the type of mutation. The 143 mutation is infrequently observed in colorectal tumors whereas the 184 and 248 mutations are more speci®c to Li-Fraumeni syndrome (Caron de Fromentel and Soussi, 1992; Hollstein et al., 1991) . Indeed, these mutations may dierently aect normal p53 functions (Farmer et al., 1992; Hinds et al., 1990; Hupp et al., 1993; Pocard et al., 1996) . Although the 143Ala mutation did not aect the G 1 /S block after irradiation of the 143X19 clone (Pocard et al., 1996) , it dominantly aected the ability of these cells to amplify CAD gene under PALA-selective pressure. This eect may be explained by the relative amounts of wild-type versus mutant p53 which might be sucient to control the cell-cycle arrest, but not to prevent gene ampli®cation. Other studies also suggested that some mutations do not confer a fully dominant phenotype in vivo since wild-type p53 activity is still observed in the presence of mutant protein (Chen et al., 1990; Frebourg et al., 1994; Levine et al., 1991; Park et al., 1994; Slingerland et al., 1993; Unger et al., 1993; Williams et al., 1995) .
If the TP53 gene represents one component of a pathway that regulates genomic stability, evidence exists that mutations of the p53 protein might not be the only way for cancer cells to acquire the ability to amplify DNA. For example, the osteosarcoma U2-OS cell line, which expresses wild-type p53, was found to be permissive for CAD ampli®cation (Smith et al., 1997) . It could be hypothesized that the pathway involving p53 would be inecient if a downstream component were inactive or that p53 is not the sole regulator of gene ampli®cation.
In conclusion, our data show that PALA-resistant colonies can be selected from either parental LoVo cells or transfected 143Ala-mutated TP53 cells. In parental LoVo cells, an increase of CAD copy number was obtained through gains of chromosome 2, whereas in transfected mutated-TP53 colonies, it was mainly obtained through chromosome 2 rearrangements. Thus, mutated TP53 cells are more permissive to chromosome rearrangements than cells with wild-type TP53 status, possibly because of a malfunctioning cell cycle checkpoint. Interestingly, these two distinct patterns of chromosome alterations of the LoVo cell line recall those of primary colorectal cancers and suggests that chromosomal evolution of colorectal cancers may depend on TP53 gene status.
Materials and methods
Cell line, transfection and culture conditions
LoVo cells were obtained from the ATCC (Rockville, MD, USA) and their mycoplasma-free status was veri®ed. Cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) (Sigma, St-Quentin-Fallavier, France) supplemented with 10% fetal calf serum (FCS) (Dutscher, Brumath, France), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine in an atmosphere of 5% CO 2 at 378C. For drug selection, FCS was dialyzed against 40 vol of phosphate-buered saline (PBS) (Sigma) for 72 h, with two changes of dialysis solution.
Cells were transfected by the pCMV-Bam-Neo derivatives SCX3 (TP53 cDNA carrying a Val?Ala substitution at position 143) kindly provided by B. Vogelstein, or by the Neo vector alone (control without TP53 cDNA). Brie¯y, 10 6 LoVo cells suspended in 800 ml of DMEM were electroporated in a Gene Pulser (Bio-Rad, Ivry sur Seine, France) at 960 mF in the presence of 10 mg of plasmid, then incubated for 1 h. Five batches were prepared using the same protocol. After washing with DMEM, each cell sample was seeded in 10-cm Petri dishes with 10 ml of 10% FCS-DMEM containing 1.2 mg/ml of freshly prepared G418 (Sigma), and incubated at 378C, in a 5% CO 2 /air humidi®ed incubator. The medium was changed every 2 days. Colonies were independently collected and expanded as cell lines in 10% FCS-DMEM containing G418 medium.
Southern blotting analysis
Detection of the integrated cDNA was performed by Southern blot of 5 mg of HindIII and EcoRI digested DNA, using radiolabeled TP53 total cDNA as a probe.
Selection of PALA-resistant colonies
To prevent the possible inactivation of the exogenous TP53 gene, all selections were performed with early passages of transfected cells. The selection procedure applied ensured that no pre-existing resistant variants could be selected and that resistant colonies were issued from recent and independent ampli®cation events. Samples of 10 3 cells, statistically devoid of pre-existant variant were grown to approximately 3610 5 cells in separate wells without selection. Cell populations of each well were independently seeded in 10-cm Petri dishes in 10% FCS-DMEM supplemented with 100 mM PALA. PALA was provided by the Drug Synthesis and Chemistry Branch, Division of Cancer Treatment (National Cancer Institute, Bethesda, MD, USA). A 90 ± 150 mM (3 ± 46LD 50 ) range of PALA concentrations was optimal for the formation of resistant colonies with few quiescent cells always remaining. Resistant colonies were visible after 6 ± 7 weeks. Since colonies from the same Petri dish were likely to be siblings, only colonies isolated from separate dishes were cloned. They were subsequently grown in PALA-containing medium, or ®xed with 10% formaldehyde, stained with Giemsa and counted.
Karyotype analysis R-banded chromosome preparations were obtained according to our usual procedure (Muleris et al., 1987) . Unstable rearrangements (chromatid and chromosome breaks, chromatid exchanges, dicentrics and telomeric associations) were scored to de®ne the rate of chromosome mutagenesis at each cell generation (Muleris and Dutrillaux, 1996) . 25 ± 100 metaphases of parental LoVo, 143X3, 143X19 and 143X20 cells, both before and after PALA selection were analysed.
Fluorescence in situ hybridization FISH was performed as described by (Muleris et al., 1994) . Brie¯y, mitotic metaphase spreads were treated with RNAse A in 26SSC at 378C for 1 h, dehydrated through an alcohol series and dried. The chromosomes were denatured in 70% formamide, 26SSC, pH 7, at 708C for 2 min, and dehydrated. The pCMV-bam-Neo derivative (normal p53 cDNA) which detects both endogenous and exogenous TP53 genes and cHuCAD69, kindly provided by B. Vogelstein and G. Stark respectively, were labeled with biotin and used as probes, both at 5 ng/ml in the hybridization mixture. A 100-fold excess of DNA competitor was necessary for cHuCAD69 hybridization. The slides were successively washed at 388C in 50% formamide-26SSC and 26SSC, 6 min each for TP53 and 10 min each for CAD. The biotinylated probes were detected by incubating the slides successively in goat antibiotin antibody (1 : 100, Vector Laboratories, Burlingame, CA, USA) and¯uoresceinated anti-goat rabbit-antibody (1 : 200, Biosys, CompieÁ gne, France) for 40 min each. Chromosomes were counterstained with 0.1 mg/ml of propidium iodide.
ELISA, Western blotting and immunocytochemistry
The total p53 protein content of the cells was analysed by Western blot using DO7 monoclonal antibody. We veri®ed by staining the blot with Red Ponceau that equivalent amount of proteins was used in each sample. The presence of total and mutant p53 protein was detected in the samples by a two-point ELISA using Ab2 and 240 monoclonal antibodies, respectively. For immunocytochemical staining, the cells were harvested in 10 mM EDTA and cytocentrifuged on slides. The slides were ®xed in formalin followed by a 1 : 1 acetone/ methanol mixture. p53 was speci®cally stained with DO7 antibody followed by a DAB detection according to a method previously described for cytological breast cancer specimens (Lesec et al., 1997) .
